Stock Market Live June 4, 2026: S&P 500 (SPY) Fall as Broadcom Sinks
Q1 26 EPS
$N/A
Est. $-2.14
Q1 26 Revenue
N/A
Est. $155.4M
vs S&P Since Q1 26
-14.6%
TRAILING MARKET
BNTX -10.0% vs S&P +4.6%
Market Reaction
Did BNTX Beat Earnings? Q1 2026 Results
BioNTech heads into its first-quarter 2026 reporting period with Wall Street modeling a loss of $2.14 per share on revenue of $155.36 million, a reflection of the steep post-pandemic decline in COVID-19 vaccine sales that has reshaped the German biot… Read more BioNTech heads into its first-quarter 2026 reporting period with Wall Street modeling a loss of $2.14 per share on revenue of $155.36 million, a reflection of the steep post-pandemic decline in COVID-19 vaccine sales that has reshaped the German biotech's financial profile. Rather than an earnings release, the company's latest filing is a formal invitation to its May 15, 2026 virtual Annual General Meeting, where shareholders will vote on a series of governance changes that illuminate BioNTech's strategic direction. Most telling is a proposed Supervisory Board expansion from six to eight members, with two new nominees bringing expertise in oncology commercialization and clinical development, signaling the company anticipates near-term product launches from its cancer pipeline. The company also seeks authorization for up to 129.51 million new shares through 2030, preserving capital-raise flexibility as it funds an ambitious slate of 15 pivotal Phase 3 oncology trials. Promising survival data from its gotistobart lung cancer program has kept analyst buy ratings intact, even as price targets have drifted lower amid the ongoing revenue transition.
BNTX Revenue by Segment
Business unit performance breakdown
BNTX Earnings Trends
BNTX vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
BNTX EPS Trend
Earnings per share: estimate vs actual
BNTX Revenue Trend
Quarterly revenue: estimate vs actual
BNTX Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 | — | $-1.95 | — | — | — |
| Q1 26 | $-2.14 | — | — | — | — |
| Q4 25 MISS FY | $-0.25 | $-1.25 | -405.66% | $907.4M | +24.34% |
| FY Full Year | $-3.44 | $-4.70 | -36.62% | $2.87B | +6.60% |
| Q3 25 MISS | $0.10 | $-0.12 | -220.36% | — | — |
| Q2 25 MISS | $-1.41 | $-1.85 | -31.65% | $301.6M | +14.39% |